CompanyXNCRNasdaqPasadena, CA

Xencor, Inc.

Xencor develops engineered antibodies using XmAb technology for cancer and autoimmune diseases.

SEC EDGAR ClinicalTrials.gov xencor.com

10-QAug 14Latest SEC filing, period to Jun 30

Aug 5Latest story

August 2026

Xencor reports Q2 2026 results, sets ESMO date for XmAb819 kidney cancer data

Aug 5Quarterly updateXencor, Inc.XMAB819

July 2026

Xencor to receive $105 million from Alexion to settle Ultomiris royalty dispute

Jul 29Partnershipravulizumab Xencor, Inc.

Xencor's Phase 1 trial of XmAb412 in healthy volunteers is recruiting

Jul 20Trial updateXencor, Inc.